Steroid treatment: the long and the short of it

Article

A study published in the March issue of Acta Ophthalmologica Scandinavica, has found that long-term treatment with a topical steroid after penetrating keratoplasty (PK) is no better at preserving endothelial cell density than short-term treatment.

A study published in the March issue of Acta Ophthalmologica Scandinavica, has found that long-term treatment with a topical steroid after penetrating keratoplasty (PK) is no better at preserving endothelial cell density than short-term treatment.

Nhung Xuan Nguyen and colleagues from the University of Erlangen-Nürnberg, Germany, compared the effects of long- and short-term topical steroid use on endothelial cell counts in 305 subjects. All patients, after undergoing PK, received prednisolone acetate 1% eye drops five times a day. This was slowly tapered over a six-month period. Patients were randomly assigned to the short-term group, which ceased steroid treatment, or the long-term group, which continued with the treatment once daily for a further 12 months.

A significant postoperative decrease in endothelial cell density was observed in both groups. At six-week follow-up, cell densities averaged 1,941 cells/mm2 in the short-term group and 1,957 cells/mm2 in the long-term group. At two-year follow-up, cell density had decreased significantly to 1,535 cells/mm2 and 1,472 cells/mm2, respectively (p<0.001).

Using linear regression, the researchers calculated that subjects in the short-term group lost an average of 216 cells/mm2 per year, while those in the long-term group lost an average of 206 cells/mm2 (p=0.5).

Analysis of the results revealed that there is no significant difference in cell density between patients on long- and short-term steroid treatment following penetrating keratoplasty.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.